The Cooper Companies Inc
COO
$70.46 1.94%
Exchange: NASDAQ | Sector: Healthcare | Industry: Medical Instruments Supplies
Q3 2024
Published: Aug 29, 2024

Earnings Highlights

  • Revenue of $1.00B up 7.8% year-over-year
  • EPS of $0.52 increased by 23.3% from previous year
  • Gross margin of 61.1%
  • Net income of 104.70M
  • ""We couldn't have reached this milestone without the hard work and dedication of our amazing employees." - Albert White" - Albert White

The Cooper Companies Inc (COO) Q3 2024 Financial Results: First Record Billion-Dollar Quarter with Strong Growth in Contact Lenses and Fertility

Executive Summary

In the third quarter of 2024, The Cooper Companies Inc achieved a historic milestone by surpassing the billion-dollar revenue mark, reporting consolidated revenues of $1.003 billion, an increase of 8% year-over-year. This impressive performance was driven primarily by record revenues in both the CooperVision and CooperSurgical segments, which rose by 10% and 5% respectively. The increase in profitability was also marked by a healthy operating margin improvement to 25.5% from 23.9% in the previous year, signifying effective cost management and operational efficiencies. Management remains optimistic about sustaining this growth trajectory into the next fiscal year, bolstered by innovative product offerings and strategic investments.

Key Performance Indicators

Revenue

1.00B
QoQ: 6.39% | YoY:7.80%

Gross Profit

612.60M
61.09% margin
QoQ: 5.46% | YoY:0.43%

Operating Income

192.50M
QoQ: 19.05% | YoY:26.98%

Net Income

104.70M
QoQ: 17.77% | YoY:22.74%

EPS

0.53
QoQ: 17.78% | YoY:23.26%

Revenue Trend

Margin Analysis

Key Insights

  • **Revenue:** $1.003 billion, up 8% YoY
  • **Gross Profit:** $612.6 million, gross margin up to 66.6% from 66.1% YoY
  • **Operating Income:** $192.5 million, operating margin at 25.5%
  • **Net Income:** $104.7 million, Net income up 22.74% YoY
  • **EPS:** $0.96 (non-GAAP), up 14% YoY

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q2 2025 1,002.30 0.44 +6.3% View
Q1 2025 964.70 0.52 +3.6% View
Q4 2024 1,018.40 0.58 +9.9% View
Q3 2024 1,002.80 0.52 +7.8% View
Q2 2024 942.60 0.44 +7.4% View